Table II.

Characteristics of study participants with Parkinson disease and self-reported nocturia (0-1 episode nightly vs. 2 or more nightly)

Variable*	Self-Reported Nocturia (0-1 episode)	Self-reported Nocturia (2 or more episodes)	p-value**
CLINICAL CHARACTERISTICS
Age (years)	N=23	N=37
	63.1 ± 7.7	63.6 ± 9.8	0.8
Gender (% male)	12 (52%)	27 (73%)	0.1
BMI (kg/m2)	N=23	N=37
	26.5 ± 6.0	28.3 ± 4.4	0.2
Hypertension	N=23	N=37
	3 (13%)	19 (51%)	0.003
Diabetes mellitus	N=23	N=37
	1 (4%)	4 (10%)	0.4
MMSE	N=23	N=37
	28.6 ± 1.5	28.5 ± 1.9	0.9
PARKINSON DISEASE CHARACTERISTICS
UPDRS (Part III)	N=21	N=30
	14.5 ± 6.4	19.7 ± 9.1	0.03
Hoehn & Yahr	N=23	N=37
	2.2 ± 0.5	2.1 ± 0.6	0.5
Total daily levodopa dose (mg)†	N=23	N=37
	359 ± 320	350 ± 379	0.9
Total daily dopamine agonist dose (mg)‡	N=23	N=37
	1.3 ± 1.5	1.5 ± 1.6	0.6
Total daily levodopa equivalents (mg)	N=23	N=37
	450 ± 366	459 ± 401	0.9
POLYSOMNOGRAPHY
Nighttime trips to the bathroom during PSG	N=20	N=34
	1.0 ± 1.0	1.76 ± 0.9	0.007
Sleep Efficiency (%)	N=20	N=34
	77.8 ± 11.8	66.6 ± 19.6	0.01
Total Sleep Time (minutes)	N=20	N=34
	380.1 ± 46.5	321.0 ± 103.7	0.02
Apnea-Hypopnea Index	N=20	N=34
	5.1 ± 6.1	6.3 ± 8.3	0.5

^*Unless indicated values represent mean ± SD

^**p-value: T-test, chi-square, or Mantel-Haenszel chi-square

UPDRS Part III: Unified Parkinson Disease Rating Scale motor score

MMSE: Mini-Mental State Exam

^†Corrected for sustained release forms of levodopa

^‡Pergolide equivalent dose